胚胎干细胞特异性分子标志

胚胎干细胞(embryonic stem cells,ES细胞)特异性分子标志是指ES细胞胞内或胞膜上特异表达的分子.已报道的包括转录因子、信号通路受体、黏附因子在内的ES细胞特异性标志与ES细胞的自我更新和全能性具有密切关系.ES细胞特异性分子标志的研究,有助于ES细胞的鉴定、分离纯化、质量控制,加快ES细胞的基础研究和临床应用.现对目前已经发现的ES细胞特异性分子标志及其研究方法和常用ES细胞分子标志的功能进行综述.     

同源域蛋白Nanog与胚胎干细胞的自我更新研究进展

胚胎干细胞作为一种具有自我更新能力的细胞,可以在体外无限对称性分裂,同时保持未分化状态,具有向各种类型细胞分化的潜能.基于这一特性,胚胎干细胞（embryonic stem cell,ES细胞）有着极其广阔的应用前景。维持ES细胞自我更新的机制至今尚未阐明,推测ES细胞的自我更新机制是一个包括细胞外刺激、细胞内多种因子共同参与的复杂的网络调节系统。近年来发现同源域蛋白Nanog在这个网络调节系统中处于中心地位,对ES细胞自我更新的维持起着关键作用。本文就近年来关于Nanog在ES细胞自我更新维持中的作用,以及它与其他信号通路之间的对话,阐明ES细胞自我更新的维持机制。     

调控胚胎干细胞自我更新的关键转录因子研究进展

胚胎干细胞（embryonic stem cells,ES细胞）具有自我更新和发育多能性的特点,在再生医学研究中有着广泛的应用前景。ES细胞多能性和自我更新的维持受到复杂的调控,涉及到转录调控、信号转导以及表观遗传调控等多个方面。转录因子Oct4、Sox2、Nanog在其中扮演着非常重要的角色,对干细胞特性的维持必不可少。本文着重讨论了这些关键转录因子的研究进展。这些研究促进了对ES细胞自我更新机制的深入理解,并为进一步的临床研究提供了理论基础。     

Cdk6在维持ES细胞自我更新中的作用

细胞周期蛋白依赖性激酶6（cyclin dependent kinase 6,Cdk6）对胚胎早期发育有着重要的作用.然而,它在胚胎干（embryonic stem,ES）细胞中的生物学功能仍不清楚.在该研究中,我们运用RNA干扰技术和基因表达分析方法探索了Cdk6在小鼠胚胎干细胞中的功能及分子机制.结果表明：Cdk6的表达水平与小鼠ES细胞的自我更新密切相关.首先,维甲酸（RA）处理和白血病抑制因子（LIF）去除实验显示 ,随着ES细胞的分化,Cdk6的表达水平明显降低.更为重要的是,RNA干扰介导的Cdk6表达抑制导致ES细胞自我更新相关基因的显著下调,同时伴随细胞分化基因的表达激活,提示Cdk6对维持ES细胞自我更新至关重要.     

干细胞命运决定的分子调控网络

来源于囊胚期胚胎内细胞团的胚胎干细胞具有独特的生物学特性,包括无限自我更新的能力以及分化为内胚层、中胚层和外胚层各种细胞的潜能.阐明胚胎干细胞全能性维持以及向各种特定细胞分化的分子机制,不仅有助于我们了解胚胎发育过程,而且将促进胚胎干细胞尽早应用于疾病治疗.本文主要就干细胞的一种命运决定过程,维持胚胎干细胞全能性或失去全能性开始分化,结合最新的研究进展讨论该过程中的分子调控网络,包括信号转导通路、表达调控网络以及表观遗传调控.     

PI3K/Akt信号通路调控胚胎干细胞的自我更新和多向分化潜能的研究进展

磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)及其下游靶点蛋白激酶B(protein kinase B,Akt/PKB)可被细胞内外一系列信号所激活,在增殖、分化、凋亡等多种细胞生物学功能的调节过程中,起着非常重要的关键信号分子的作用。近年来研究显示,I型PI3K和其下游分子Akt/PKB所组成的信号通路与胚胎干细胞(embryonic stem cells,ES细胞)自我更新和多向分化潜能的维持密切相关。深入研究ES细胞自我更新和多向分化潜能的维持及其分子机制,是其应用于细胞替代治疗、再生医学和组织工程的基础。本文着重对PI3K/Akt信号通路调控ES细胞自我更新和多向分化潜能的研究进展进行综述。     

胚胎干细胞体外分化心肌细胞的研究

胚胎干细胞是从动物胚胎内细胞团分离的具有全能性的细胞.研究证明分离的小鼠胚胎干细胞在体外可以分化成心肌细胞,这一发现为小鼠胚胎干细胞向各种特化心脏细胞(动脉样细胞、血管样细胞、窦样细胞、心室样细胞、蒲肯野氏样细胞)分化提供了依据,使基因功能的研究在体外成为可能.1998年末人类ES细胞的成功培养奠定了心脏细胞的再生性治疗的战略基础.主要综述了目前ES细胞体外分化心肌细胞的进程,讨论了此进程对心脏基因研究的促进作用.     

MicroRNAs与胚胎干细胞研究

MicroRNAs(miRNAs)是一种大小约20～25个碱基的非编码小分子RNA,一般通过特异性抑制靶蛋白翻译或降解靶基因mRNA发挥负调控基因表达的作用.胚胎干细胞(embryonic stem cells,ES细胞)是从植入前早期胚胎内细胞团或原始生殖细胞中分离得到并能在体外长期培养的高度未分化的多能细胞系,在揭示胚胎早期发育机理、药物筛选、临床再生医学等领域具有广泛的应用前景.最近研究发现miRNAs在ES细胞自我更新和分化过程中均发挥着重要的调控作用,但具体调控机制尚未完全阐明.进一步深入研究miRNAs在ES细胞中的作用,全面了解ES细胞自我更新和定向分化的机制是实现ES细胞广阔临床应用前景的基础.     

维持胚胎干细胞多能性的分子机制

胚胎干细胞（ES细胞）来源于早期发育的胚胎,具有分化为任何细胞类型的多能性,因此具有巨大的基础研究及潜在的应用前景.目前认为ES细胞主要通过一些外源性信号分子的作用及某些重要的内源性转录因子的表达共同起作用来达到其维持多能性的目的.外源性信号分子LIF、BMP4以及Wnt等介导的信号传导通路与内源性转录因子Oct4、Nanog、Sox2、FoxD3等共同起作用来抑制那些促进ES细胞分化的基因表达和激活那些有助于维持ES细胞多能性维持的基因表达,进而形成一个相互调控和依存的基因调控网络共同维持ES细胞的多能性.     

动物胚胎干细胞诱导分化的研究进展

胚胎干细胞 (ES细胞 )是从动物早期胚胎的内细胞团或原始生殖细胞分离出来的具有发育全能性的一种未分化的无限增殖细胞系 ,ES细胞能体外诱导分化为神经细胞、肌肉细胞、成纤维细胞等各种细胞。综述了动物的ES细胞的分化诱导机理及目前体外诱导分化的研究现状     

The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells

Embryonic stem (ES) cells derived from the inner cell mass (ICM) of blastocysts grow infinitely while maintaining pluripotency. Leukemia inhibitory factor (LIF) can maintain self-renewal of mouse ES cells through activation of Stat3. However, LIF/Stat3 is dispensable for maintenance of ICM and human ES cells, suggesting that the pathway is not fundamental for pluripotency. In search of a critical factor(s) that underlies pluripotency in both ICM and ES cells, we performed in silico differential display and identified several genes specifically expressed in mouse ES cells and preimplantation embryos. We found that one of them, encoding the homeoprotein Nanog, was capable of maintaining ES cell self-renewal independently of LIF/Stat3. nanog-deficient ICM failed to generate epiblast and only produced parietal endoderm-like cells. nanog-deficient ES cells lost pluripotency and differentiated into extraembryonic endoderm lineage. These data demonstrate that Nanog is a critical factor underlying pluripotency in both ICM and ES cells.     

Design of the artificial acellular feeder layer for the efficient propagation of mouse embryonic stem cells

Embryonic stem (ES) cells are pluripotent-undifferentiated cells that have a great interest for the investigation of developmental biology. Murine ES cells maintain their pluripotency by the supplementation of the leukemia inhibitory factor (LIF). LIF is reported to act as a matrix-anchored form, and immobilized cytokines are useful to sustain their signaling on target cells. In this study, we used the immobilizable fusion protein composed of LIF and IgG-Fc region, which was used as a model of the matrix-anchored form of LIF to establish a novel system for ES cell culture and to investigate the effect of immobilized LIF on maintenance of ES cell pluripotency. Mouse ES cells maintained their undifferentiated state on the surface coated with LIF-Fc. Furthermore, when cultured on the co-immobilized surface with LIF-Fc and E-cadherin-Fc, mouse ES cells showed characteristic scattering morphologies without colony formation, and they could maintain their undifferentiated state and pluripotency without additional LIF supplementation. The activation of LIF signaling was sustained on the co-immobilized surface. These results indicate that immobilized LIF and E-cadherin can maintain mouse ES cells efficiently and that the immobilizable LIF-Fc fusion protein is useful for the investigation of signaling pathways of an immobilized form of LIF in the maintenance of ES cell pluripotency.     

Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency

Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells represent a promising therapeutic tool for many diseases, including aged tissues and organs at high risk of failure. However, the intrinsic self-renewal and pluripotency of ES and iPS cells make them tumorigenic, and hence, the risk of tumor development hinders their clinical application. Here, we present a novel approach to limit their tumorigenicity and increase their safety through increased copy number of tumor suppressors. iPS containing an extra copy of the p53 or Ink4a/ARF locus show normal pluripotency, as determined by in vitro and in vivo differentiation assays. Yet, while retaining full pluripotency, they also possess an improved engagement of the p53 pathway during teratocarcinoma formation, which leads to a reduced tumorigenic potential in various in vitro and in vivo assays. Furthermore, they show an improved response to anticancer drugs, which could aid in their elimination in case tumors arise with no adverse effects on cell function or aging. Our system provides a model for studying tumor suppressor pathways during reprogramming, differentiation, and cell therapy applications. This offers an improved understanding of the pathways involved in tumor growth from engrafted pluripotent stem cells, which could facilitate the use of ES and iPS cells in regenerative medicine.     

Effects of feeder layer and BRL conditioned medium on mouse embryonic stem cells

In vitro growth and maintenance of embryonic stem (ES) cell lines derived from ICM cells of various blastocysts of 129 strain mice,the sustenance of their pluripotency and normal karyotype depend on the feeder layer of mouse embryonic fibroblasts (MEF).Compared with the feeder layer of MEF cells,medium conditioned by Buffalo rat liver cells (BRL-CM) is able to maintain pluripotency and karyotypic normality of ES cells only in short term cell propagation.Besides,ES cells grown in BRL-CM are also capable of aggregation with 8-cell embryos of Swiss strain and develop into germ line chimaeras.Modification to the method of aggregating ES cells with early embryos by making a hole in agar layer on the top of MEF feeder cells was shown to be more converient and efficient than the conventional microdrop method.     

Methods for iPS cell generation for basic research and clinical applications

The induction of pluripotency can be achieved by forced expression of defined factors in somatic cells. The established cells, termed induced pluripotent stem (iPS) cells, have pluripotency and an infinite capacity for self-renewal in common with embryonic stem (ES) cells. Patient-specific iPS cells could be a useful source for drug discovery and cell transplantation therapies; however, the original method for iPS cell generation had several issues that were obstacles to their clinical application. Recent studies have brought about various improvements for iPS cell generation and uncovered several characteristics of iPS cells. Here we summarize the current status of iPS cell studies, with a focus on the improved methods that can be used to generate iPS cells, and also refer to the future challenges.